CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced the appointment of Francois Nader, M.D., M.B.A, as the Chairman of its Board of Directors. Dr. Nader joined the Acceleron Board in December 2014.
"We are very pleased to appoint Dr. Nader as Chairman. His extensive background in drug development and his success in leading an organization through late stage development into global commercialization in rare diseases will be an important asset for Acceleron as we enter this exciting stage of corporate growth"
"We are very pleased to appoint Dr. Nader as Chairman. His extensive background in drug development and his success in leading an organization through late stage development into global commercialization in rare diseases will be an important asset for Acceleron as we enter this exciting stage of corporate growth," said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
Dr. Nader is a 30-year veteran of the healthcare industry. Dr. Nader served as President, Chief Executive Officer and Director of NPS Pharma through the recent acquisition of NPS by Shire. During his tenure, Dr. Nader transformed NPS Pharma into a leading global rare disease company. He joined NPS Pharma in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior to that, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader currently serves as immediate past chairman of the Board of Trustees for BioNJ, New Jersey's trade organization representing the biotechnology industry. He is also a Board member of the New Jersey Chamber of Commerce, Trevena, Inc. (TRVN) and Clementia Pharmaceuticals. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
Acceleron Pharma Inc.
Kevin F. McLaughlin, 617-649-9204
Senior Vice President and Chief Financial Officer
Suda Communications LLC
Maureen L. Suda, 585-387-9248